The EU’s rapid and unanimous approval of Valneva’s #Chikungunya vaccine, IXCHIQ, following recommendation by the European Medicines Agency last month is a historic moment to help protect the lives and livelihoods of European populations against outbreaks of Chikungunya, which are becoming more frequent and widespread in the region. Supported by CEPI and EU funding, IXCHIQ is the world’s first vaccine offering protection against the debilitating and long-neglected Chikungunya disease. But the fight is not over. “As a matter of priority CEPI is working with Valneva and the EU to expand access to doses to those living in endemic countries who are most at risk from the disease” explains CEPI CEO Dr @Richard Hatchett in today’s press release. Find out more about how CEPI and partners are accelerating access to doses ➡️ https://lnkd.in/eGw7E6kq
Valneva Receives Marketing Authorization in Europe for the World’s First Chikungunya Vaccine, IXCHIQ® https://lnkd.in/dakdaghM
